NO994364L - Dolastatin 15 derivater med karbonyl og heterocykliske funksjonaliteter ved C-terminal ende - Google Patents

Dolastatin 15 derivater med karbonyl og heterocykliske funksjonaliteter ved C-terminal ende

Info

Publication number
NO994364L
NO994364L NO994364A NO994364A NO994364L NO 994364 L NO994364 L NO 994364L NO 994364 A NO994364 A NO 994364A NO 994364 A NO994364 A NO 994364A NO 994364 L NO994364 L NO 994364L
Authority
NO
Norway
Prior art keywords
group
dolastatin
carbonyl
derivatives
terminal end
Prior art date
Application number
NO994364A
Other languages
English (en)
Other versions
NO994364D0 (no
Inventor
Kurt Ritter
Wilhelm Amberg
Teresa Barlozzari
Andreas Haupt
Bernd Janssen
Andreas Kling
Original Assignee
Basf Ag
Basf Bioresearch Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag, Basf Bioresearch Corp filed Critical Basf Ag
Publication of NO994364D0 publication Critical patent/NO994364D0/no
Publication of NO994364L publication Critical patent/NO994364L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet nye peptider nyttige som anti-cancermidler. Forbindelsene som er beskrevet, har formel (l): A - B - D - D - F - G; A, B, D og E er a-aminosyre- residier. l en utførelsesform er F en azacykloalkankarboksylsyrerest. l denne utførelsesformen er G en enverdig rest, for eksempel et hydrogenatom, en alkyl- f gruppe, en arylgruppe eller en heteroarylgruppe. l en annen utførelsesform er F ert azacykloalkylgruppe og G er en heteroarylgruppe koblet til F med en karbon-karbon- binding. l en annen utførelsesform er det beskrevet en fremgangsmåte for behandling av cancer i et pattedyr, så som et menneske, omfattende administrering til pattedyret en effektiv mengde av en forbindelse med formel (l) i en farmasøytisk akseptabel blanding.
NO994364A 1997-03-10 1999-09-09 Dolastatin 15 derivater med karbonyl og heterocykliske funksjonaliteter ved C-terminal ende NO994364L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/814,577 US5965537A (en) 1997-03-10 1997-03-10 Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
PCT/US1998/004317 WO1998040400A1 (en) 1997-03-10 1998-03-05 Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the c-terminus

Publications (2)

Publication Number Publication Date
NO994364D0 NO994364D0 (no) 1999-09-09
NO994364L true NO994364L (no) 1999-11-09

Family

ID=25215470

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994364A NO994364L (no) 1997-03-10 1999-09-09 Dolastatin 15 derivater med karbonyl og heterocykliske funksjonaliteter ved C-terminal ende

Country Status (17)

Country Link
US (1) US5965537A (no)
EP (1) EP0981539A1 (no)
JP (1) JP2001518084A (no)
KR (1) KR20000076099A (no)
CN (1) CN1252806A (no)
AR (1) AR011957A1 (no)
AU (1) AU744511B2 (no)
BR (1) BR9808017A (no)
CA (1) CA2297164A1 (no)
CO (1) CO4950525A1 (no)
HR (1) HRP980124A2 (no)
HU (1) HUP0001758A3 (no)
IL (1) IL131596A0 (no)
NO (1) NO994364L (no)
TW (1) TW505657B (no)
WO (1) WO1998040400A1 (no)
ZA (1) ZA981957B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1392291B1 (en) 2000-10-30 2007-05-30 Janssen Pharmaceutica N.V. Tripeptidyl peptidase inhibitors
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
DE10240818A1 (de) * 2002-08-30 2004-05-13 Grünenthal GmbH Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
FR2856685B1 (fr) * 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
ES2579323T3 (es) 2007-07-16 2016-08-09 Genentech, Inc. Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso
CN105001334A (zh) 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
ES2960619T3 (es) 2014-02-28 2024-03-05 Hangzhou Dac Biotech Co Ltd Enlazadores cargados y sus usos para la conjugación
WO2016086357A1 (en) * 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Methyl oxazole orexin receptor antagonists
US9987255B2 (en) 2014-12-19 2018-06-05 Merck Sharp & Dohme Corp. 5,5-bicyclic oxazole orexin receptor antagonists
CN104952808A (zh) * 2015-06-12 2015-09-30 广州先艺电子科技有限公司 一种预置金锡盖板及其制造方法
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN110099682B (zh) 2016-11-14 2023-03-31 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
CN109776342A (zh) * 2019-02-26 2019-05-21 北京大学深圳研究生院 顺式β-氨基酸及其衍生物的合成方法
BR112022005289A2 (pt) * 2019-10-17 2022-09-20 Givaudan Sa Azaciclos substituídos como moduladores de trmp8
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US5091368A (en) * 1990-08-08 1992-02-25 Harbor Branch Oceanographic Institution, Inc. Biologically active compounds from blue-green algae
DK0934950T3 (da) * 1991-08-09 2002-07-29 Teikoku Hormone Mfg Co Ltd Tetrapeptidderivat
CZ292612B6 (cs) * 1992-05-20 2003-11-12 Abbott Gmbh & Co. Kg Peptid s protirakovinnou aktivitou, jeho použití a farmaceutický prostředek s obsahem takového peptidu
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
HUT72067A (en) * 1992-12-16 1996-03-28 Basf Ag Dolostatin analog
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof

Also Published As

Publication number Publication date
IL131596A0 (en) 2001-01-28
EP0981539A1 (en) 2000-03-01
CA2297164A1 (en) 1998-09-17
HUP0001758A3 (en) 2001-12-28
AU744511B2 (en) 2002-02-28
HRP980124A2 (en) 1998-12-31
AU6448298A (en) 1998-09-29
NO994364D0 (no) 1999-09-09
BR9808017A (pt) 2000-03-08
KR20000076099A (ko) 2000-12-26
US5965537A (en) 1999-10-12
TW505657B (en) 2002-10-11
CO4950525A1 (es) 2000-09-01
ZA981957B (en) 1999-09-09
AR011957A1 (es) 2000-09-13
CN1252806A (zh) 2000-05-10
HUP0001758A2 (hu) 2001-05-28
JP2001518084A (ja) 2001-10-09
WO1998040400A1 (en) 1998-09-17

Similar Documents

Publication Publication Date Title
NO994364L (no) Dolastatin 15 derivater med karbonyl og heterocykliske funksjonaliteter ved C-terminal ende
DE69530936T2 (de) Boronsäure-und-esterverbindungen, deren systhese und verwendungen
US4692458A (en) Anti-hypertensive agents
DE69319432T2 (de) Peptide aus Derivaten der 4-Amino-2.2.-Difluoro-3-Oxo-1.6-Hexandisäure als Wirkstoffe gegen Entzündungen
NO20000231L (no) Dolastatin-15-derivater
DE19914474A1 (de) Aminosäurederivate
EP0035383B1 (en) Angiotensin converting enzyme inhibitors
EP0315574A2 (de) Renin-Inhibitoren
US4745124A (en) Orally effective anti-hypertensive agents
NO943852L (no) Fremgangsmåte for å hemme bentap
EA010852B1 (ru) Пиперидиновые соединения и фармацевтические композиции, их содержащие
DE69431359T2 (de) Prolyl-endopeptidaseinhibitoren
DE3840452A1 (de) (beta)-amino-boronsaeure-derivate
KR100593601B1 (ko) 성장호르몬 방출성을 가진 화합물
DE19632773A1 (de) Neue Thrombininhibitoren
EP0508220B1 (de) Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel
DE69424846T2 (de) Zyklische Aminosäure-Derivate mit ACE und NEP inhibierender Aktivität
CA2315679A1 (en) Vitamin e derivatives
DE3913272A1 (de) Dipeptid-derivate mit enzym-inhibitorischer wirkung
NZ336793A (en) Method for stabilizing peptides by adding an organic acid and then lyophilizing the peptide mixture
NO20044964L (no) Flytende preparat som omfatter camptothecinderivat og farmasoytisk preparat som kan fremstilles ved a lyofilisere preparatet
DE3842067A1 (de) Enzym-hemmende aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
DE69625230T2 (de) Thrombininhibitoren
WO1998004278A3 (en) Tetrapeptide derivatives of dolastatin as antitumor agents
DE3839126A1 (de) Renin-hemmende harnstoffderivate von dipeptiden, verfahren zu deren herstellung, diese enthaltende mittel und ihre verwendung